Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.66 |
| ▸ | NPC1 | O15118 | 3/20 | 0.66 |
| ▸ | RAB9A | P51151 | 3/20 | 0.66 |
| ▸ | TP53 | P04637 | 2/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.65 |
| ▸ | HTT | P42858 | 1/20 | 0.65 |
| ▸ | MAOB | P27338 | 9/20 | 0.63 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.63 |
| ▸ | MAOA | P21397 | 1/20 | 0.60 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.60 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.60 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.60 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | CASP7 | P55210 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17212246 | 1.00 | MAPT (0.66) | MAPTNPC1RAB9ATP53SMN1; SMN2 | |
| SCHEMBL4939430 | 0.86 | ABCG2 (0.65) | NPC1RAB9AABCG2 | |
| SCHEMBL4933533 | 0.86 | ABCG2 (0.65) | NPC1RAB9AABCG2 | |
| SCHEMBL4933565 | 0.86 | ABCG2 (0.65) | MAPTNPC1RAB9ATP53SMN1; SMN2 | |
| SCHEMBL4933573 | 0.86 | ABCG2 (0.65) | MAPTNPC1RAB9ATP53SMN1; SMN2 | |
| SCHEMBL691132 | 0.86 | NPC1 (0.69) | MAPTNPC1RAB9ATP53SMN1; SMN2 | |
| SCHEMBL691131 | 0.86 | NPC1 (0.69) | MAPTNPC1RAB9ATP53SMN1; SMN2 | |
| SCHEMBL9036957 | 0.85 | GAA (0.57) | MAPTNPC1RAB9ATP53SMN1; SMN2 | |
| SCHEMBL9036952 | 0.85 | GAA (0.57) | MAPTNPC1RAB9ATP53SMN1; SMN2 | |
| SCHEMBL2225311 | 0.84 | NPC1 (0.63) | MAPTNPC1RAB9ATP53SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3398585-B1 | EXTERNAL DERMAL COMPOSITION FOR ANTI-AGEING AND METHOD FOR PRODUCING THE SAME | HAYASHIBARA CO (JP) | 2020-02-26 | — | — | EP | disclosed |
| US-10550142-B2 | Quercetin-based compound | AMOREPACIFIC CORPORATION (KR) | 2020-02-04 | — | — | US | disclosed |
| US-20190241601-A1 | NOVEL QUERCETIN-BASED COMPOUND | AMOREPACIFIC CORPORATION (KR) | 2019-08-08 | — | — | US | disclosed |
| US-10309212-B2 | Energetic cocrystals for treatment of a subterranean formation | HALLIBURTON ENERGY SERVICES, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-10253244-B2 | Scale-inhibiting cocrystals for treatment of a subterranean formation | HALLIBURTON ENERGY SERVICES, INC. (US) | 2019-04-09 | — | — | US | disclosed |
| US-20190008747-A1 | EXTERNAL DERMAL COMPOSITION FOR ANTI-AGEING AND METHOD FOR PRODUCING THE SAME | Hayashibara Co., Ltd. (JP) | 2019-01-10 | — | — | US | disclosed |
| EP-3398585-A1 | EXTERNAL DERMAL COMPOSITION FOR ANTI-AGEING AND METHOD FOR PRODUCING THE SAME | Hayashibara Co., Ltd. (JP) | 2018-11-07 | — | — | EP | disclosed |
| US-10111822-B2 | External dermal composition for anti-ageing and method for producing the same | Hayashibara Co., Ltd. (JP) | 2018-10-30 | — | — | US | disclosed |
| EP-2939657-B1 | SKIN-EXTERIOR ANTI-AGEING COMPOSITION AND PRODUCTION METHOD THEREFOR | HAYASHIBARA CO (JP) | 2018-08-08 | — | — | EP | disclosed |
| US-10006151-B2 | Polyurethane fiber | TORAY OPELONTEX CO., LTD. (JP) | 2018-06-26 | — | — | US | disclosed |
| EP-2292585-A1 | Screening for solid forms by ultrasound crystallization and cocrystallization using ultrasound | APTUIT (KANSAS CITY), LLC (US) | 2011-03-09 | — | — | EP | disclosed |
| US-20090281195-A1 | NOVEL COCRYSTALLIZATION | S.S.C.I., INC. (US) | 2009-11-12 | — | — | US | disclosed |
| US-20090087401-A1 | DEODORANT COMPOSITION | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2009-04-02 | — | — | US | disclosed |
| US-7452555-B2 | Cocrystallization | S.S.C.I., INC. (US) | 2008-11-18 | — | — | US | disclosed |
| US-20080095721-A1 | Natural sunscreen compositions and processes for producing the same | HIMALAYA GLOBAL HOLDINGS LIMITED (AE) | 2008-04-24 | — | — | US | disclosed |
| US-7311896-B2 | Natural sunscreen compositions and processes for producing the same | MMI CORPORATION (KY) | 2007-12-25 | — | — | US | disclosed |
| US-20070287194-A1 | Screening For Solid Forms By Ultrasound Crystallization And Cocrystallization Using Ultrasound | S.S.C.I., INC | 2007-12-13 | — | — | US | disclosed |
| US-20070088508-A1 | Cocrystallization methods | APTUIT (WEST LAFAYETTE), LLC | 2007-04-19 | — | — | US | disclosed |
| US-20060165622-A1 | Deodorant composition | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2006-07-27 | — | — | US | disclosed |
| EP-1561476-A1 | DEODORANT COMPOSITION | Takasago International Corporation (JP) | 2005-08-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190241601-A1 | NOVEL QUERCETIN-BASED COMPOUND | TEAD3, TEAD4, TEAD2 | MAPT 237/4885NPC1 4180/4885RAB9A 1287/4885 |
| US-10550142-B2 | Quercetin-based compound | TEAD3, TEAD4, TEAD2 | MAPT 202/4885NPC1 4089/4885RAB9A 1361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.